This content is machine translated Rheumatologic overlap syndrome When RA, SSc and SLE strike together Overlap syndromes, which include systemic scleroderma (SSc), rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), are rare. When the symptoms of the three autoimmune diseases occur simultaneously, this overlap poses…
View Post 5 min This content is machine translated Systemic lupus erythematosus DORIS and LLDAS are also worthwhile for severe cases DORIS (Definition of Remission in SLE) and LLDAS (Lupus Low Disease Activity State) are established measures of remission in systemic lupus erythematosus (SLE), but their feasibility and validity have not…
View Post 4 min This content is machine translated Casuistry SLE with kidney damage does not always have to be lupus nephritis The distinction between IgA nephropathy and lupus nephritis in patients with systemic lupus erythematosus (SLE) has important prognostic and therapeutic implications. Physicians from China describe a case of systemic lupus…
View Post 4 min This content is machine translated SLE: Early use of biologics? Findings from the “Leeds SLE Inception Cohort” If systemic lupus erythematosus (SLE) cannot be adequately controlled with hydroxychloroquine and cortisone preparations, the use of immunomodulatory or immunosuppressive agents and/or biologics should be considered according to current EULAR…
View Post 4 min This content is machine translated Systemic lupus erythematosus Protection against relapses, even without remission The line between low disease activity and remission in systemic lupus erythematosus is often imprecise. The question remains to what extent this can play a role for outcomes such as…
View Post 4 min This content is machine translated Systemic lupus erythematosus The future belongs to precision medicine The multiple disease manifestations of systemic lupus erythematosus (SLE) are essentially a consequence of autoantibodies, immune complexes, and cytokines. New therapies specifically intervene in the immunopathogenesis of the complex autoimmune…
View Post 6 min This content is machine translated Systemic lupus erythematosus What can belimumab and anifrolumab do? The monoclonal antibodies belimumab and anifrolumab are both approved for the treatment of systemic lupus erythematosus (SLE). Their response is considered to be highly effective. The point at which they…
View Post 5 min This content is machine translated Systemic lupus erythematosus (SLE) Anifrolumab: 3-year data confirm long-term clinical benefit New data from a long-term extension study show that anifrolumab was effective, safe, and tolerable in systemic lupus erythematosus (SLE) even in long-term use over three years [1]. Two post-hoc…
View Post 6 min This content is machine translated Systemic Lupus Erythematosus New weapons in the fight against SLE Systemic Lupus Erythematosus (SLE) is often a major challenge not only for those affected, but also for physicians. Despite numerous therapeutic options, treatment is usually a tightrope walk between dangerous…
View Post 5 min This content is machine translated Systemic lupus erythematosus (SLE) Besides Belimumab, other biologics soon available for the treatment of SLE? The therapeutic options available today allow the choice of an individualized therapeutic strategy. In addition to covventional immunosuppressants, biologics are becoming increasingly important. Belimumab has been approved as an add-on…
View Post 8 min This content is machine translated Systemic lupus erythematosus New possibilities for SLE therapy The core of the previous classification criteria for systemic lupus erythematosus (SLE) originated in 1982 and were only slightly modified in 1997. It is therefore high time to address the…
